Hepatocellular carcinoma (HCC) is one of the most common malignancies with high global mortality. Yttrium-90 selective internal radiation therapy (90Y-SIRT) is a precision radio-interventional treatment whose efficacy and safety critically depend on accurate microsphere delivery and dose distribution. This review provides an overview of imaging techniques used in 90Y-SIRT, emphasizing both single-modality and multimodal approaches. We summarize the clinical value of ultrasound, CT, MRI, angiography, and nuclear medicine, each providing anatomical, functional, or metabolic information. We further discuss multimodal imaging integration across the treatment workflow: pre-procedural fusion supports patient selection and dose planning; intraprocedural volumetric imaging guides catheter placement; and post-treatment functional imaging assesses microsphere distribution and therapeutic response. By consolidating current evidence, this review highlights the clinical utility of multimodal imaging and identifies areas for optimization in treatment planning, procedural guidance, and outcome assessment of 90Y-SIRT. This synthesis serves as a practical reference for clinicians and researchers aiming to improve the precision and effectiveness of radioembolization for HCC.
90Yclinical applicationhepatocellular carcinomamultimodal imagingradioembolizationThe author(s) declared that financial support was not received for this work and/or its publication.section-at-acceptanceCancer Imaging and Image-directed InterventionsIntroduction
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer-related deaths worldwide (1). Due to its insidious clinical presentation, a substantial proportion of patients are diagnosed at intermediate or advanced stages, and less than 30% are candidates for curative treatments at initial diagnosis (2, 3). Consequently, locoregional therapies play a pivotal role in the multidisciplinary management of HCC (4). Yttrium-90 selective internal radiation therapy (90Y-SIRT) has emerged as an important locoregional treatment option that can be applied across various stages of HCC (5, 6). By selectively delivering radioactive microspheres into tumor-feeding arteries, 90Y-SIRT achieves high-dose internal irradiation of tumor tissue through the emission of high-energy β-particles, while relatively sparing non-tumorous liver parenchyma (7). Nevertheless, given the high radioactivity of 90Y microspheres, treatment efficacy and safety are critically dependent on precise microsphere delivery (8). Inaccurate administration or ectopic embolization may lead to severe complications or even death (8, 9). As a result, the successful implementation of 90Y-SIRT requires meticulous patient selection, accurate pre-procedural assessment of vascular anatomy, microsphere distribution, and dosimetry, as well as reliable intra-procedural guidance and post-treatment monitoring (5). In clinical practice, however, individual imaging modalities each provide complementary but incomplete information regarding tumor anatomy, vascular complexity, extrahepatic shunting, and microsphere distribution (10). Conventional anatomical imaging, angiographic techniques, and nuclear medicine imaging each provide distinct but inherently limited information, particularly with regard to accurately depicting microsphere distribution and predicting radiation dose delivery (10). Multimodal imaging, defined as the integration of two or more imaging modalities into a single framework, enables the fusion of anatomical, functional, and molecular information, providing more accurate diagnostic and therapeutic guidance than any single imaging technique (11). In the context of 90Y-SIRT, multimodal imaging supports the entire treatment continuum.
This review aims to provide a modality-oriented overview of imaging techniques used in 90Y-SIRT for HCC, summarizing the clinical value of single-modality imaging and the role of multimodal imaging in procedural guidance and treatment optimization. By systematically integrating information across different imaging modalities, this review highlights their complementary strengths and provides a comprehensive perspective on how multimodal imaging can improve treatment planning, dose delivery, and outcome prediction. As shown in Figure 1, we outline recent advances and challenges in the application of multimodal imaging throughout the 90Y-SIRT workflow, highlighting its pivotal role in treatment planning, efficacy optimization, and the prospects for future development.
Multimodal imaging techniques across the yttrium-90 selective internal radiation therapy (90Y-SIRT) workflow for hepatocellular carcinoma. This schematic summarizes the roles of different imaging modalities at each stage of 90Y-SIRT, from pre-procedural planning through intra-procedural navigation to post-treatment assessment. Solid circles denote core imaging guiding therapy; circles with surrounding squares indicate complementary or optional imaging. Abbreviations: 90Y-SIRT, yttrium-90 selective internal radiotherapy; US, ultrasound; CEUS, contrast-enhanced ultrasound; CBCT, cone-beam CT; Angio-CT, angiography CT; PET/CT, positron emission tomography/CT, SPECT/CT, single-photon emission computed tomography/CT.
Multimodal imaging techniques across the 90Y-SIRT workflow are detailed in three stages: pre-procedural planning, intra-procedural navigation, and post-treatment assessment. Each stage features corresponding imaging modalities and objectives. Pre-procedural planning includes patient selection and tumor evaluation. Intra-procedural navigation focuses on catheter positioning and microsphere delivery optimization. Post-treatment assessment involves dosimetry evaluation and long-term follow-up. Illustrations show liver images at each stage, depicting arterial anatomy, catheter placement, and necrosis evaluation. Imaging techniques like US/CEUS, CT, MRI, and PET/CT are categorized by primary and adjunctive modalities.Cross-sectional anatomical imaging in <sup>90</sup>Y-SIRTUS based imaging
Ultrasound (US) serves as the primary surveillance modality for patients at risk of HCC, acting as the initial screening tool before patients are considered for 90Y-SIRT. While B-mode US is non-invasive, its utility for treatment planning is restricted by variable image quality. Schoenberger et al. reported that nearly 18% of patients with cirrhosis present with moderate-to-severe visualization limitations, with high body mass index and non-alcoholic fatty liver disease identified as independent risk factors for inadequate imaging (12). Consequently, clinical guidelines mandate that any nodule ≥ 10 mm detected on US requires further characterization with multiphasic cross-sectional imaging to confirm the diagnosis (13, 14).
To address these limitations, contrast-enhanced ultrasound (CEUS) has been integrated into diagnostic algorithms to resolve indeterminate findings. Hawley et al. highlight that newer ultrasound contrast agents, such as perflubutane, possess a unique post-vascular Kupffer phase (15). These agents are phagocytosed by Kupffer cells in healthy parenchyma but not by malignant cells, enabling “defect reperfusion imaging” that facilitates whole-liver assessment and improves the detection of occult nodules missed by standard B-mode US (15).
In the specific workflow of 90Y-SIRT, CEUS provides a distinct advantage for early post-treatment monitoring. Unlike bland embolization, 90Y microspheres (20-30 μm) do not fully occlude tumor-feeding vessels, allowing residual intratumoral blood flow to be evaluated by CEUS (16). Delaney et al. demonstrated that quantitative CEUS could predict long-term response as early as 2 weeks post-treatment, significantly earlier than the standard 3–6 months interval required for morphological changes on CT or MRI (16). In their study, responders exhibited a significant decrease in fractional vascularity of approximately 38% at 2 weeks, whereas non-responders showed unchanged or increased vascularity (16). Thus, CEUS serves as a critical adjunctive modality for monitoring early hemodynamic changes following radioembolization.
CT based techniques
Multidetector computed tomography (MDCT) serves as the standard modality for the initial staging and vascular mapping of hepatocellular carcinoma (HCC) prior to Yttrium-90 (90Y) radioembolization. Due to its rapid acquisition speed and high spatial resolution, multiphasic CT is indispensable for defining hepatic arterial anatomy and calculating liver volumes for dosimetry. A recent multicenter study by Yoon et al. reported that contrast-enhanced CT achieved a sensitivity of approximately 75% for diagnosing HCC under LI-RADS criteria, performing comparably to gadoxetic acid-enhanced MRI in scenarios where washout timing is critical (17). However, conventional CT remains limited in characterizing small hypovascular nodules (< 2 cm) compared to MRI, and standard morphological evaluation often fails to predict microvascular invasionpreoperatively (18).
To enhance diagnostic capabilities, dual-energy CT (DECT) has been introduced to differentiate materials based on their energy-related attenuation characteristics. Silva et al. highlight that DECT can generate material density images, such as iodine and water maps (19). These maps allow for the reconstruction of virtual unenhanced images, potentially eliminating the need for a true non-contrast phase and reducing radiation dose (19). Furthermore, monochromatic images generated by DECT improve the contrast-to-noise ratio, aiding in the distinction of true contrast enhancement from hemorrhage or calcification, which is particularly valuable in complex post-treatment scenarios (19).
In the specific context of post-90Y-SIRT assessment, DECT addresses the limitations of size-based criteria, as radioembolization is cytostatic and tumors often do not shrink immediately despite necrosis. Altenbernd et al. demonstrated that quantifying iodine uptake via DECT is a superior biomarker for response compared to morphological criteria (20). In their prospective study, iodine uptake classification identified 26 partial responders, whereas standard American Association for the Study of Liver Diseases criteria identified only 8 responders within the same cohort (20). By visualizing the loss of vascularity rather than mere shrinkage, DECT provides a more accurate indication of therapeutic success (20).
Beyond spectral imaging, CT radiomics and CT liver perfusion (CTLP) offer functional insights into tumor microcirculation. Zhong et al. developed a radiomics model that achieved high accuracy (AUC 0.890) in preoperatively predicting microvascular invasion and relapse-free survival in HCC ≥ 3 cm (21). Regarding perfusion parameters, Hayano et al. showed that HCCs exhibit significantly higher blood volume than hypovascular metastases but lower values than hypervascular metastases (22). Additionally, Kalarakis et al. found that optimizing CTLP protocols could reduce radiation exposure by nearly 50% without compromising diagnostic accuracy (23). In post-treatment monitoring, Reiner et al. found that a significant decrease in arterial perfusion on CTLP 4 weeks after radioembolization correlated with improved 1-year survival in patients with liver metastases (24).
MRI based techniques
MRI serves as the reference standard for the diagnosis, treatment planning, and response assessment of HCC in the context of 90Y-SIRT, owing to its superior soft-tissue contrast and multiparametric functional capabilities. The application of hepatobiliary-specific contrast agents, such as gadoxetic acid (Gd-EOB-DTPA), significantly refines diagnostic accuracy by exploiting organic anion transporting polypeptides (OATP). Since HCC cells typically lack functional OATP1B3 expression, most HCC lesions appear hypointense during the hepatobiliary phase, thereby improving lesion conspicuity and facilitating the detection of iso- or hypovascular tumors (25). A head-to-head meta-analysis confirms this superiority, demonstrating a pooled sensitivity of 86% for Gd-EOB-DTPA-enhanced MRI compared to 70% for MDCT (26). This advantage is critical for small lesions; for tumors ≤ 1 cm, MRI sensitivity (46%) is more than double that of CT (20%) (26). Diagnostic performance of MRI remains guideline-dependent; applying Asian Pacific Association for the Study of the Liver criteria yields a sensitivity of 89.3%, whereas LI-RADS criteria reduce sensitivity to 70.6% but ensure a specificity of 90.4%, minimizing false-positive allocations for radioembolization (17).
Diffusion-weighted imaging (DWI) provides functional information by probing the random Brownian motion of water molecules, which is inversely correlated with tissue cellularity and cell membrane integrity. Malignant tumors typically exhibit restricted diffusion due to high cellular density, resulting in high signal intensity on high b-value images and low values on the quantitative apparent diffusion coefficient (ADC) map (25, 27). As an advanced application of diffusion sequences, intravoxel incoherent motion (IVIM) imaging utilizes multiple b-values to distinguish true molecular diffusion from perfusion-related pseudo-diffusion (28, 29). This allows for the simultaneous assessment of tissue cellularity and capillary microcirculation without the need for intravenous contrast, providing a unique non-invasive perspective on the tumor microenvironment prior to and following embolization (27).
Dynamic contrast-enhanced MRI (DCE-MRI) is the gold standard for the quantitative assessment of tumor vascularity, analyzing the pharmacokinetics of contrast agent distribution to derive parameters such as the volume transfer constant and arterial flow (29). Given that 90Y-SIRT relies on the exclusive arterial supply of HCCs, DCE-MRI provides direct mechanistic insights into therapeutic efficacy. Technological advancements like golden-angle radial sparse parallel (GRASP) acquisition have overcome traditional temporal resolution limitations (30). GRASP enables free-breathing perfusion imaging that yields quantitative parameters, such as arterial liver perfusion and hepatic perfusion index, which demonstrate excellent agreement with volume perfusion CT (ICC ≥ 0.88) but without the associated ionizing radiation (30).
For 90Y-SIRT procedural planning, precise target definition is a prerequisite for accurate dosimetry. Conventional anatomical sequences may suffer from inter-observer variability. The application of multisource adaptive MRI fusion, which computationally synthesizes T1-weighted, T2-weighted, and DWI data, elevates the tumor contrast-to-noise ratio to 9.82, vastly superior to the 0.72 of planning CT (31). This fusion technique improves the consistency of gross tumor volume delineation, achieving a Dice similarity coefficient of 0.95 (31, 32). Additionally, baseline texture analysis (radiomics) of DCE-MRI maps offers prognostic value; high intratumoral heterogeneity in arterial fraction has been identified as a robust predictor of long-term complete response to radioembolization (AUC = 0.857) [7].
Post-procedural response assessment with MRI addresses the inherent limitations of anatomical criteria. Following 90Y-SIRT, tumors often undergo coagulation necrosis without immediate shrinkage; studies indicate no significant change in tumor size at 30 days post-treatment (mean 9.4 cm to 9.2 cm), rendering standard RECIST criteria insensitive in the early phase [9]. Conversely, functional metrics respond rapidly. A reduction in arterial enhancement by approximately 22% is an early sign of devascularization [9]. Similarly, IVIM imaging can detect significant decreases in arterial flow and pseudodiffusion coefficients as early as 6 weeks post-treatment (28). Critically, quantitative ADC changes have prognostic value: an increase in ADC greater than 30% at 30 days post-treatment is a potent predictor of objective response (sensitivity 90%) and correlates with significantly prolonged median overall survival (13.9 months vs. 5.5 months in non-responders) (33). However, hemorrhagic necrosis can cause high T1 signal intensity on pre-contrast images, obscuring viable tumor enhancement. Image subtraction techniques effectively mitigate this confounder, improving the sensitivity for detecting complete tumor necrosis to 78.1%, compared to only 28.1% with non-subtracted images (34).
Angiographic imaging techniques in <sup>90</sup>Y-SIRT
Angiographic imaging constitutes the procedural backbone of 90Y-SIRT, essential not only for intra-procedural guidance but also for pre-treatment vascular mapping and flow dynamic assessment. Once a patient is deemed eligible, a comprehensive angiographic evaluation is performed to document hepatic arterial anatomy and identify tumor-feeding vessels. This step is critical for detecting hazardous extrahepatic branches or anastomoses that could lead to non-target microsphere deposition, thereby allowing for catheter repositioning or prophylactic embolization when necessary (35).
Digital subtraction angiography
DSA remains the reference standard for pre-procedural vascular mapping. A thorough understanding of hepatic arterial variants is a prerequisite for successful radioembolization, as the standard anatomy (Michels Type I) accounts for only 55%-75% of cases (36, 37). Failure to recognize variants, such as replaced or accessory hepatic arteries, may compromise the accuracy of lung shunt estimation and result in incomplete tumor coverage. Furthermore, large peripherally located HCCs frequently recruit parasitic blood supply from extrahepatic sources, most commonly the right inferior phrenic artery (38). Overlooking these collateral feeders precludes complete tumor treatment and necessitates comprehensive angiographic interrogation beyond the celiac axis (38).
In the context of 90Y-SIRT, the primary utility of DSA lies in safety and hemodynamic assessment. It is essential for identifying vessels supplying the gastrointestinal tract, specifically the gastroduodenal artery, right gastric artery, and cystic artery—to prevent complications like gastric ulceration or cholecystitis (10, 38). Concurrently, DSA identifies tumor-feeding vessels and evaluates real-time hemodynamics to detect potential flow reversal caused by large hypervascular tumors; these findings collectively guide the optimal catheter positioning for the subsequent injection of Technetium-99m macroaggregated albumin (99mTc-MAA) (38).
Despite its central role, DSA has inherent limitations. As a two-dimensional projection technique, it may obscure complex vascular overlaps and fail to detect small collateral vessels, necessitating the adjunctive use of volumetric imaging (10). Additionally, DSA is highly operator-dependent; its diagnostic accuracy and safety profile rely heavily on the interventionalist’s experience in recognizing subtle vascular anomalies and achieving stable microcatheter positioning for super-selective delivery.
Cone-beam CT and angiography CT
Volumetric intraprocedural imaging, encompassing CBCT and Angio-CT, has evolved from an adjunctive tool to a critical component of the 90Y-SIRT workflow. By providing three-dimensional soft-tissue visualization directly in the interventional suite, these modalities overcome the limitations of two-dimensional DSA in assessing vascular complexity and perfusion territories. The precise identification of tumor-feeding arteries and extrahepatic shunts is paramount for safety, yet reliance on DSA alone often results in the misclassification of vascular supply, particularly in anatomically complex regions like hepatic segments I and IV. In a study of 42 patients, Louie et al. found that CBCT revealed extrahepatic enhancement or incomplete tumor perfusion in 52% of cases, with 33% of these findings being exclusive to CBCT and undetectable by DSA (39). Heusner et al. further validated this diagnostic superiority, demonstrating that CBCT achieved a specificity of 96% and an accuracy of 90% for detecting extrahepatic shunts, compared to 88% and 81% for DSA, respectively (40). Consequently, intraprocedural volumetric imaging facilitates immediate preventative embolization of aberrant vessels, such as the falciform or right gastric arteries, significantly reducing the risk of gastrointestinal ulceration.
Beyond safety, volumetric imaging is essential for optimizing dosimetry by delineating the microcatheter-perfused liver volume, which often differs from anatomical lobes defined by venous landmarks on pre-procedural CT. Rhee et al. established that using catheter-directed CT angiography to calculate segmental volumes rather than standard lobar volumes resulted in a significantly higher calculated effective tumor dose (348 Gy vs. 100 Gy) (41). Grözinger et al. reported that angiographic prediction of segmental blood supply differed from the actual perfusion territory defined by volumetric imaging in 27.3% of patients, resulting in a mean mismatch volume of 90 ± 54 mL. This discrepancy led to dose calculation differences ranging from approximately 11% to 14% for both glass and resin microspheres, depending on the treated liver lobe (42). Furthermore, Jafargholi Rangraz et al. showed that discrepancies between anatomical and perfusion-based liver lobe segmentation derived from contrast-enhanced CBCT could result in substantial absorbed dose differences, reaching up to 21 Gy for the left lobe and 9 Gy for the right lobe (43). These findings highlight the importance of CBCT-based perfusion territory segmentation for accurate definition of liver vascular supply in dosimetric calculations.
While CBCT is widely available, it is limited by a restricted field of view, susceptibility to motion artifacts, and low contrast resolution. Angio-CT systems, which integrate a fan-beam CT scanner with an angiography suite, address these limitations. Tanaka et al. noted that Angio-CT offers a larger field of view (up to 50 cm) and high-contrast resolution superior to CBCT, mitigating truncated-view artifacts in large patients, albeit at a higher equipment cost and radiation dose (44). Lionberg et al. emphasized that Angio-CT eliminates the need for breath-holding and provides diagnostic-quality multi-phasic imaging, enabling the detection of occult satellite lesions and more precise volumetric delineation for dosimetry (45). Emerging quantitative applications of Angio-CT are also being explored. Campbell et al. reported that the tumor enhancement ratio measured on Angio-CT showed a moderate correlation with the final 90Y microsphere distribution observed on positron emission tomography (PET) (r = 0.34), which performed comparably to standard 99mTc-MAA single-photon emission computed tomography (SPECT) -based prediction (r = 0.32) (46). These findings suggest that angio-CT may serve as a quantitative adjunct to conventional imaging for dosimetric assessment and prediction of microsphere distribution, thereby supporting more individualized treatment planning.
Nuclear medicine imaging for dosimetry and planning in <sup>90</sup>Y-SIRT
Nuclear medicine imaging represents the functional backbone of 90Y-SIRT, shifting clinical focus from purely morphological assessment to metabolic and physiological characterization. This “theranostic” approach comprises two distinct phases: pre-treatment simulation using 99mTc-MAA to predict microsphere distribution, and post-treatment verification imaging to validate actual Yttrium-90 deposition. While SPECT has traditionally served as the workhorse for dosimetry and treatment planning, the advent of SPECT/CT hybrid imaging and PET/CT has substantially improved accuracy and enabled more personalized therapy (Figure 2).
Post-procedural dose verification. Images in a 56-year-old man with hepatocellular carcinoma demonstrate that the intratumoral distribution of 90Y microspheres was essentially consistent with the pretreatment 99mTc-MAA prediction. (A) Axial contrast-enhanced CT image (arterial phase) shows an arterially enhancing lesion (arrow) in the right hepatic lobe, corresponding to hepatocellular carcinoma. (B) Axial Angio-CT image obtained after superselective catheterization of the posterior branch of the right hepatic artery again shows the arterially enhancing lesion (arrow). (C) Selective angiogram of the posterior branch of the right hepatic artery shows appropriate catheter position (arrow) for 99mTc-MAA delivery. (D) Coregistered 99mTc-MAA SPECT/CT and CT image shows essentially complete tumoral distribution of the 99mTc-MAA (arrow). (E) Coregistered posttherapy 90Y bremsstrahlung and pretherapy CT image similarly demonstrates similar intratumoral distribution of 90Y microspheres (arrow).
A series of five abdominal CT images labeled A to E. Image A shows a liver lesion with noticeable contrast enhancement. Image B depicts a larger, enhanced liver mass. Image C presents an angiography illustrating a feeding vessel to the liver tumor. Image D combines CT and PET scans highlighting increased metabolic activity in the liver lesion. Image E displays a PET/CT fusion with vivid color indicative of high activity in the liver region. Each image has an arrow pointing to the area of interest.SPECT/CT imaging
SPECT/CT systems integrate functional data with detailed anatomical localization, overcoming the limitations of planar scintigraphy, such as poor spatial resolution and the lack of tissue attenuation correction. In the context of HCC, where tumor vascularity is complex and often distorted by underlying cirrhosis, this multimodal integration is critical for precise vascular mapping and quantitative dosimetry.
<sup>99m</sup>Tc- MAA SPECT/CT
99mTc-MAA scintigraphy serves as the mandatory surrogate for simulating microsphere distribution, assessing arterial perfusion, and detecting extrahepatic shunting prior to 90Y-SIRT. While planar imaging was historically used, SPECT/CT has demonstrated superior diagnostic performance. Ahmadzadehfar et al. reported that SPECT/CT significantly improved the sensitivity for identifying extrahepatic shunting to 100%, compared to 41% for SPECT and 32% for planar imaging alone (47). Crucially, these findings altered the therapeutic management in 29% of patients, involving coil embolization of aberrant vessels or catheter repositioning, whereas planar imaging only impacted 7.8% of cases (47).
For the detection of gastrointestinal shunting, which poses a risk of severe ulceration, Kao et al. demonstrated that SPECT/CT achieved a sensitivity of 100% and an accuracy of 96%, far exceeding the 25% sensitivity of planar imaging (48). Lenoir et al. further detailed that SPECT/CT effectively identifies non-target uptake in specific anatomical sites, including the gallbladder (12.2%) and the hepatic artery (6.5%) (49). Notably, SPECT/CT is vital for characterizing HCC with portal vein thrombosis; tracer accumulation within the portal vein thrombosis was identified in 6.5% of scans, confirming arterial supply to the thrombus and eligibility for therapy (49).
Quantitative 99mTc-MAA SPECT/CT also plays a pivotal role in personalized dosimetry. Garin et al. established that a tumor-absorbed dose threshold of 205 Gy is highly predictive of treatment response. Patients receiving doses ≥ 205 Gy achieved a significantly prolonged median overall survival of 18 months, compared to 9 months in those receiving lower doses (50). Regarding safety, a lung shunt fraction exceeding 20% typically precludes treatment to prevent radiation pneumonitis (Figure 3). However, accurate lung dosimetry allows for treatment in selected cases if the estimated lung dose remains below 30 Gy per session and 50 Gy cumulatively (51). Despite its utility, potential pitfalls such as coregistration errors, observed in 2.1% of cases, require careful image interpretation to avoid false-positive diagnoses (49).
Importance of performing a pre-procedural 99mTc-MAA shunt scan. A 76-year-old man presented with a large hepatocellular carcinoma involving the middle hepatic vein, without extrahepatic disease. (A) Axial contrast-enhanced T1-weighted MR image (arterial phase) shows an arterially enhancing lesion (arrow) in the right hepatic lobe, corresponding to hepatocellular carcinoma. (B) Axial Angio-CT image (arterial phase) demonstrates early opacification of the main portal vein (arrow), indicating the presence of an arterioportal shunt. (C) Digital subtraction angiography performed prior to 99mTc-MAA administration shows the catheter positioned in the superior mesenteric artery. Early opacification of the main portal vein (arrow) is again seen during the arterial phase due to a high-flow shunt during contrast injection. (D)99mTc-MAA maximum intensity projection image shows radiotracer activity distributed throughout the right hepatic lobe (white arrow) and in both lungs (black arrows), reflecting extensive portal shunting. The lung shunt fraction was 40.868%, exceeding the safety threshold for 90Y radioembolization, and therefore treatment was cancelled.
Panel A shows an arterial-phase contrast-enhanced MRI image with a white arrow indicating a hyperenhancing liver tumor. Panel B displays an arterial-phase Angio-CT image demonstrating early opacification of the portal vein, suggesting an arterioportal shunt. Panel C presents a digital subtraction angiography image showing catheter positioning and contrast reflux into the portal vein during arterial injection. Panel D shows a ⁹⁹ᵐTc-MAA maximum intensity projection image with radiotracer uptake throughout the right hepatic lobe and both lungs (arrows), indicating extensive hepatopulmonary shunting, with a lung shunt fraction of 40.868%.Post-treatment <sup>90</sup>Y SPECT/CT
Post-treatment imaging of 90Y relies on the detection of bremsstrahlung radiation produced by the interaction of β-particles with tissue, as 90Y lacks discrete gamma emissions for conventional scintigraphy. While this modality serves as the standard for verifying microsphere deposition, it is technically challenging due to the continuous and broad energy spectrum of bremsstrahlung photons, which leads to significant scatter, septal penetration, and low spatial resolution (52). To mitigate these limitations, Uliel et al. recommend the use of medium-energy collimators and a narrowed energy window to improve image quality and prevent the overestimation of lung shunt fractions caused by scatter (52).
The primary clinical utility of post-treatment 90Y SPECT/CT lies in its ability to correct false-positive findings observed on pre-treatment MAA scans, thereby confirming the safety of the procedure. Lenoir et al. demonstrated that while 99mTc-MAA SPECT/CT identified gallbladder uptake in 17 cases and hepatic artery uptake in 9 cases, post-treatment 90Y bremsstrahlung imaging confirmed actual microsphere deposition in only 1 case for each site (49). This discrepancy highlights that MAA often overestimates the risk of non-target embolization due to vascular spasms or catheter positioning differences, whereas post-treatment SPECT reflects the true biodistribution (49).
Regarding dosimetry, systematic deviations exist between the predictive 99mTc-MAA model and the actual 90Y distribution (53) (Figure 4). Wondergem et al. analyzed 39 procedures and found that 68% of liver segments showed a difference greater than 10% between activity predicted by 99mTc-MAA and actual 90Y activity, with catheter tip positioning identified as a significant factor influencing this disagreement (54). Similarly, Debebe et al. reported that the mean tumor-to-normal liver ratio (TNR) derived from 99mTc-MAA (9.4) was significantly higher than that measured on post-treatment 90Y SPECT (5.0), suggesting that 99mTc-MAA tends to overestimate tumor uptake (55). This tendency was corroborated by recent studies. Cheng et al. found that pre-treatment 99mTc-MAA SPECT/CT yielded a higher median TNR (5.8) compared to post-treatment verification imaging (4.9), although it accurately predicted the absorbed dose to normal liver tissue (56). Similarly, Demir et al. observed that while 99mTc-MAA SPECT/CT provided reliable dose estimates for healthy liver parenchyma, it showed lower accuracy for tumor-absorbed doses, with D90 values calculated via SPECT being systematically higher than those from PET-based verification (57). In terms of volumetric dosimetry, achieving the minimum dose to 70% of the tumor volume (D70) of 95 Gy has been associated with objective response, whereas non-responders had a significantly lower mean D70 of 60 Gy (58). However, due to the inherent quantitative limitations of bremsstrahlung imaging, Elschot et al. noted that SPECT underestimates the dose in small lesions by up to 75%, necessitating the adoption of more advanced modalities like PET/CT for precise voxel-based dosimetry (59).
An example of disagreement between tumor dose between predictive and post-treatment dosimetry. (A, B) Pre-treatment image (99mTc-MAA-SPECT/CT). (C, D) Post-treatment image (90Y-PET/MR); the tumor contoured in pink: predictive and post-treatment dose assessment were comparable (pre-treatment predicted: mean dose: 84 Gy, D50 = 83 Gy and V100 = 39%; post-treatment: mean dose: 95 Gy, D50 = 84 Gy and V100 = 44%); the tumor contoured in yellow: predictive dosimetry underestimated the tumor dose (pre-treatment predicted: mean dose: 33 Gy, D50 = 33 Gy and V100 = 0%; post-treatment measurement: mean dose: 130 Gy, D50 = 125 Gy and V100 = 67%); and the tumor contoured in red: predictive dosimetry over-estimated the tumor dose (pre-treatment predicted: mean dose: 165 Gy, D50 = 159 Gy and V100 = 86%; post-treatment: mean dose: 4 Gy, D50 = 2 Gy and V100 = 0%). (E) Dose-volume histogram of the described VOIs based on predictive and post-treatment dose assessments. In this case a different catheter positioning between MAA work-up and treatment resulted in flow variation. A preferential targeting of the tumor in the ventral part of the right liver lobe (red tumor) was observed in the work-up. On the other hand, after 90Y-microsphere injection, a preferential targeting of the tumor in the dorsal part of the left liver lobe was obtained. This is one example of a potential pitfall in SIRT in general and a cause of discrepancy between 99mTc-MAA and 90Y-PET in particular (53). Reproduced from Jafargholi Rangraz E et al., EJNMMI Physics, 2020, CC BY 4.0.
Medical imaging analysis showing four panels labeled A to D with color-coded tumor regions on grayscale scans. Panel E presents a dose-volume histogram graphing tumor treatment predictions and measurements for pink, yellow, and red regions, with absorbed dose on the x-axis and volume percentage on the y-axis.PET/CT imagingTumor biology and risk stratification
While conventional anatomical imaging guides catheter navigation, PET/CT provides critical insights into tumor metabolic activity and biological aggressiveness, serving as a powerful tool for patient selection and risk stratification. Although 18F-fluorodeoxyglucose (18F-FDG) PET has limited sensitivity (50-65%) for detecting well-differentiated HCC due to high glucose-6-phosphatase activity, Filippi et al. emphasize its value in identifying aggressive, poorly differentiated phenotypes that are associated with microvascular invasion and poor outcomes (60).
High FDG uptake is a robust independent predictor of survival, often outperforming traditional staging systems. In a multicenter cohort of 291 patients with BCLC stage C HCC, Na et al. demonstrated that patients with a low tumor-to-liver uptake ratio (TLR < 3.0) had a median overall survival of 14.9 months, significantly longer than the 6.4 months observed in patients with high TLR (61). In the specific context of 90Y-SIRT, Jreige et al. reported that metabolic parameters are superior to morphological criteria for predicting long-term survival. In their study, patients with low maximum standardized uptake value achieved a median overall survival of 30.9 months, compared to only 9 months for those with high metabolic activity (P = 0.02) (62). These findings suggest that patients with high FDG avidity represent a high-risk subgroup that may require treatment intensification or combination therapy.
For well-differentiated tumors that are often FDG-negative, ¹¹C-acetate or 18F-fluorocholine (18;F-FCH) serve as effective surrogates for cell membrane biosynthesis, offering higher sensitivity for detection (60). Furthermore, PET/CT is highly effective for early risk stratification post-treatment. Reizine et al. showed that early evaluation (4–8 weeks post-SIRT) using 18F-FDG or 18F-FCH PET/CT could predict 6-month response with 100% sensitivity and 100% specificity, whereas standard mRECIST assessment at 1 month showed lower diagnostic accuracy (63).
Post-treatment <sup>90</sup>Y PET/CT
Although Yttrium-90 is a pure beta-emitter, it undergoes a minor decay branch (approximately 32 per million decays) generating internal pair production, which allows for direct imaging of microsphere biodistribution using PET scanners (64). This modality overcomes the fundamental resolution limitations of bremsstrahlung SPECT. Elschot et al. quantitatively compared the two modalities in a phantom study, demonstrating that while SPECT underestimated the absorbed dose in small spheres (10 mm) by 75%, Time-of-flight (TOF) PET reduced this underestimation to 45%, while achieving an error rate of only 11%in larger spheres (37 mm) (59). Furthermore, the multicenter QUEST phantom study confirmed that current-generation TOF-PET scanners can consistently reconstruct 90Y activity concentrations; however, activity concentrations in small structures (≤ 37 mm) are systematically underestimated, by approximately 20% for spheres larger than 20 mm, due to partial volume effects (65).
The superior spatial resolution of 90Y PET/CT facilitates precise voxel-based dosimetry and the generation of dose-volume histograms (DVH), which are critical for predicting treatment efficacy. Kao et al. analyzed post-treatment PET dosimetry in HCC patients and identified a clear dose-response relationship: complete tumor responses were generally achieved when D70 exceeded 100 Gy, while non-responders typically had a D70 below 100 Gy (64). This study also established safety thresholds, noting that a mean dose of 49 Gy to the stomach was associated with gastritis, while 18 Gy was asymptomatic (64). A recent systematic review by Roosen et al. further corroborated these findings, suggesting that a target mean dose of 100–250 Gy is generally required to induce a response in HCC, a threshold significantly higher than that for colorectal liver metastases (40–60 Gy) (66). Additionally, post-treatment PET dosimetry correlates well with metabolic response; Levillain et al. reported a strong correlation (R² = 0.82) between the mean absorbed dose and the reduction in total lesion glycolysis, identifying 39 Gy and 60 Gy as key metabolic response thresholds (67).
Recent technological advancements, such as long axial field-of-view (LAFOV) PET/CT systems, further enhance the utility of post-treatment imaging by offering higher sensitivity and total-body coverage. Linder et al. demonstrated that LAFOV systems allow for a reduced scan duration of 20 minutes while maintaining adequate image quality and quantification accuracy for dosimetry (68). However, challenges remain in voxel-wise dosimetry algorithms. In a 2025 comparative study, Zeimpekis et al. reported that despite the high sensitivity, current voxel-wise algorithms on LAFOV systems may significantly underestimate the delivered dose compared to pre-treatment SPECT planning. Specifically, the median tumor D90 measured by LAFOV PET was significantly lower than that predicted by SPECT (30.5 Gy vs 123.5 Gy), suggesting that further refinement of dosimetric tools is necessary to fully leverage this advanced technology for accurate absolute dose quantification (69).
Multimodal imaging integration across the <sup>90</sup>Y-SIRT workflow
The precision of 90Y-SIRT relies on the accurate definition of the biological target volume during the pre-procedural phase, a task where the integration of anatomical and functional imaging significantly outperforms single-modality assessment (11). While CT serves as the standard for vascular mapping, it often fails to capture the full extent of viable tumor burden in cirrhotic livers. Basha et al. demonstrated that a combined CT and MRI protocol yields a diagnostic accuracy of 91.29%, significantly superior to the 67.6% accuracy of CT alone (70). This multimodal approach is particularly critical for characterizing “borderline” hepatic nodules; Joo et al. revealed that 44.0% of hepatobiliary phase hypointense nodules without arterial enhancement—often dismissed as benign on standard CT—are pathologically confirmed as progressed HCC (71). Consequently, integrating hepatobiliary phase MRI with 99mTc-MAA SPECT/CT is essential for personalized dosimetry. Although 99mTc-MAA SPECT/CT generally correlates well with final 90Y biodistribution, Cheng et al. cautioned that it tends to overestimate the tumor-to-normal ratio in the left hepatic lobe, necessitating the cross-referencing of functional SPECT data with high-resolution anatomical MRI to prevent non-target radiation (56).
Translating these complex pre-operative plans into precise catheter delivery requires real-time intra-procedural navigation, where volumetric imaging acts as the vital link between diagnostic planning and angiographic execution. The application of “fusion guidance”, which overlays pre-operative cross-sectional volumes onto live fluoroscopy, transforms 2D angiography into a 3D navigational environment. Within this workflow, the joint application of functional and anatomical modalities is decisive. Rodríguez-Fraile et al. highlighted that integrating intra-procedural CBCT with pre-treatment 99mTc-MAA SPECT/CT optimizes dosimetric planning; specifically, the anatomical detail from CBCT compelled a modification of the treatment plan—such as the splitting of administered activity—in 42% of patients with multiple feeding arteries, ensuring complete tumor coverage that would have been ambiguous on SPECT alone (72) (Figure 5). Furthermore, fusing unenhanced CBCT with pre-treatment contrast-enhanced CT enhances the sensitivity for detecting small viable tumor foci to 96.5%, significantly superior to the 78.6% sensitivity of standard MDCT (73), thereby minimizing the risk of geographic miss during the intervention.
(a) Contrast-enhanced computed tomography (CECT) image: HCC located between segments IV and VIII. (b)99mTc-MAA SPECT/CT fusion image shows low uptake in the lateral part of the tumoral nodule. 99mTc-MAA activity was split in two doses of 50% each by IR decision, based on liver and tumoral volumes. (c, c1 and c2) C-arm cone-Beam CT (CBCT) volumetric assessment of the tumoral territory perfused by each artery. VIII segments artery (in green) fed only 32% of the tumoral volume while IV segment artery fed most of it (in orange). (d)90Y PET/CT fusion image after splitting the activity according to CBCT volumes shows the adequate distribution of the microspheres throughout the lesion (80). Reproduced from Rodríguez−Fraile et al., EJNMMI Research, 2021, CC BY 4.0.
Medical imaging of the liver in various panels. Panel a shows a CT scan with a visible mass. Panel b highlights a PET scan with colored regions indicating metabolic activity. Panel c displays another scan with crosshairs centered on an abnormal area. Panel c1 shows a 3D reconstruction with green and orange segments. Panel c2 presents another 3D view emphasizing textured areas. Panel d combines PET and CT scans identifying a bright, active region.
Following the procedure, the focus shifts to quantitative verification, where the superior spatial resolution of PET-based modalities allows for voxel-level dosimetric validation that far exceeds the capabilities of traditional Bremsstrahlung SPECT. 90Y PET/CT has established a clear dose-response relationship, with Kokabi et al. identifying a mean absorbed tumor dose of 253 Gy as a robust threshold for predicting objective response (AUC = 0.929) (74). Moving beyond average doses, the emergence of simultaneous PET/MRI offers a deeper insight into dose heterogeneity. Demir et al. reported that while pre-treatment SPECT accurately predicts the dose to normal liver parenchyma, it fails to capture the non-uniformity of microsphere deposition within the tumor; post-treatment 90Y PET/MRI detected significantly higher “hot spot” doses compared to SPECT/CT (57). This capability to generate accurate DVH allows clinicians to distinguish between true dosimetric failure and heterogeneous coverage, as validated by Fowler et al. in predicting individual lesion response (75).
Finally, functional imaging provides a critical advantage in the early post-treatment window by detecting physiological responses that precede morphological tumor shrinkage. Traditional size-based criteria such as RECIST are often insensitive in the first few months due to treatment-induced edema and necrosis. In contrast, functional changes serve as immediate biomarkers of efficacy. Rhee et al. demonstrated that DWI can predict response as early as 1-month post-treatment, where a 10.5% increase in ADC values identified responders with 93% sensitivity (76). Similarly, CEUS offers an accessible bedside alternative; Delaney et al. showed that CEUS can detect a significant reduction in fractional vascularity (approximately 38%) in responders as early as 2 weeks after therapy (16). These functional metrics enable the early identification of non-responders, facilitating timely adjunctive therapies rather than waiting for delayed anatomical progression.
Conclusions and future perspectives
The evolution of Yttrium-90 radioembolization for hepatocellular carcinoma marks a paradigm shift where therapeutic efficacy increasingly depends on the depth and integration of imaging data. The transition from empirical treatment to precision oncology relies on a multimodal imaging framework transcending simple anatomical visualization. While conventional modalities like angiography and CT provide essential vascular roadmaps, they offer incomplete insights into tumor biology and metabolic activity when used in isolation. The synergistic application of functional imaging (DWI, CEUS) and molecular imaging (SPECT/CT, PET/CT) is therefore critical for constructing a comprehensive “theranostic” profile. This integration facilitates accurate definition of the biological target volume, reducing risks of geographic miss and non-target embolization.
Multimodal imaging is perhaps most valuable in mitigating inherent procedural uncertainties. Synthesizing pre-procedural functional data with intra-procedural volumetric imaging creates a validation loop, ensuring the treatment plan aligns with the actual vascular territory. The growing adoption of post-treatment quantitative validation, particularly voxel-based 90Y-PET/CT dosimetry, provides a robust mechanism to correlate absorbed dose with pathological response. This shift towards quantitative dosimetry transforms imaging from a passive observation tool into an active biomarker of therapeutic success, distinguishing technical limitations from biological non-response.
Looking forward, the maturation of 90Y-SIRT will hinge on standardizing quantitative imaging protocols across institutions to ensure reproducibility (77). Technical advancements, such as simultaneous PET/MRI systems, offer a promising avenue to further refine dosimetric accuracy by minimizing motion-related registration errors and improving soft-tissue contrast (75). Additionally, the emerging field of radiomics and artificial intelligence represents a potential supplementary tool for treatment optimization. Rather than replacing conventional interpretation, these computational analyses may help uncover subtle, non-invasive imaging phenotypes capable of predicting tumor aggressiveness or radio-resistance (78). The future of 90Y-SIRT lies in the continued refinement of this multimodal ecosystem, where imaging data drives a personalized, predictable, and effective therapeutic strategy for patients with hepatocellular carcinoma.
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesSungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalA.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660, PMID: 33538338WangYDengB.
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Met Rev. (2023) 42:629–52. doi: 10.1007/s10555-023-10084-4, PMID: 36729264Department of Medical Administration NHCotPsRoC.
Guideline for diagnosis and treatment of primary liver cancer (2024 edition). Chin J Dig Surg. (2024) 23:429–78.
InchingoloRPosaAMariappanMSpiliopoulosS.
Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol. (2019) 25:4614–28. doi: 10.3748/wjg.v25.i32.4614, PMID: 31528090SalemRMazzaferroVSangroB.
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. (2013) 58:2188–97. doi: 10.1002/hep.26382, PMID: 23512791SalemRGabrARiazAMoraRAliRAbecassisM.
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. (2018) 68:1429–40. doi: 10.1002/hep.29691, PMID: 29194711JiangZYangFWangW.
Applications of yttrium-90 (90Y) in hepatocellular carcinoma. OncoTargets Ther. (2024) 17:149–57. doi: 10.2147/OTT.S445898, PMID: 38414759RiazAAwaisRSalemR.
Side effects of yttrium-90 radioembolization. Front Oncol. (2014) 4:198. doi: 10.3389/fonc.2014.00198, PMID: 25120955ControlBNMQCenterICommitteeNM.
Chinese expert consensus on selective internal radiation therapy with yttrium-90 for primary and metastatic hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi= Zhonghua Ganzangbing Zazhi= Chin J Hepatol. (2021) 29:648–58. doi: 10.3760/cma.j.cn501113-20210302-00103, PMID: 34371535CamachoJCMoncayoVKokabiNReaveyHEGaltJRYamadaK.
(90)Y radioembolization: multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery. Radiographics. (2015) 35:1602–18. doi: 10.1148/rg.2015140314, PMID: 26230755LeeSYJeonSIJungSChungIJAhnC-H.
Targeted multimodal imaging modalities. Adv Drug Deliv Rev. (2014) 76:60–78. doi: 10.1016/j.addr.2014.07.009, PMID: 25064554SchoenbergerHChongNFetzerDTRichNEYokooTKhatriG.
Dynamic changes in ultrasound quality for hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol. (2022) 20:1561–9.e4. doi: 10.1016/j.cgh.2021.06.012, PMID: 34119640BruixJShermanM.
Management of hepatocellular carcinoma: an updateΔσ. Hepatology. (2011) 53:1020–2. doi: 10.1002/hep.24199, PMID: 21374666SparchezZCraciunRCaraianiCHorhatANenuIProcopetB.
Ultrasound or sectional imaging techniques as screening tools for hepatocellular carcinoma: fall forward or move forward? J Clin Med. (2021) 10. doi: 10.3390/jcm10050903, PMID: 33668839HawleyJTangYSjöströmAFuentes-AlburoATranquartF.
The clinical utility of liver-specific ultrasound contrast agents during hepatocellular carcinoma imaging. Ultrasound Med Biol. (2025) 51:415–27. doi: 10.1016/j.ultrasmedbio.2024.10.011, PMID: 39674715DelaneyLJTantawiMWessnerCEMaChadoPForsbergFLyshchikA.
Predicting long-term hepatocellular carcinoma response to transarterial radioembolization using contrast-enhanced ultrasound: initial experiences. Ultrasound Med Biol. (2021) 47:2523–31. doi: 10.1016/j.ultrasmedbio.2021.05.006, PMID: 34130880YoonJHChangWKimYKLeeCHKimJWParkBJ.
Comparison of gadoxetic acid-enhanced liver magnetic resonance imaging and contrast-enhanced computed tomography for the noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer. (2025) 14:638–50. doi: 10.1159/000545965, PMID: 40487794KieransASKangSKRosenkrantzAB.
The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: A meta-analysis. Radiology. (2016) 278:82–94. doi: 10.1148/radiol.2015150177, PMID: 26098460SilvaACMorseBGHaraAKPadenRGHongoNPavlicekW.
Dual-energy (spectral) CT: applications in abdominal imaging. Radiographics. (2011) 31:1031–46. doi: 10.1148/rg.314105159, PMID: 21768237AltenberndJWetterAForstingMUmutluL.
Treatment response after radioembolisation in patients with hepatocellular carcinoma-An evaluation with dual energy computed-tomography. Eur J Radiol Open. (2016) 3:230–5. doi: 10.1016/j.ejro.2016.08.002, PMID: 27622200ZhongHZhangYZhuGZhengXWangJKangJ.
Preoperative prediction of microvascular invasion and relapse-free survival in hepatocellular Carcinoma ≥3 cm using CT radiomics: Development and external validation. BMC Med Imaging. (2025) 25:141. doi: 10.1186/s12880-025-01677-2, PMID: 40312321HayanoKDesaiGSKambadakoneARFuentesJMTanabeKKSahaniDV.
Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion. Cancer Imaging. (2013) 13:512–9. doi: 10.1102/1470-7330.2013.0040, PMID: 24334461KalarakisGPerisinakisKAkoumianakisEKarageorgiouIHatzidakisA.
CT liver perfusion in patients with hepatocellular carcinoma: can we modify acquisition protocol to reduce patient exposure? Eur Radiol. (2021) 31:1410–9. doi: 10.1007/s00330-020-07206-9, PMID: 32876834ReinerCSMorsbachFSahBRPuippeGSchaeferNPfammatterT.
Early treatment response evaluation after yttrium-90 radioembolization of liver Malignancy with CT perfusion. J Vasc Interv Radiol. (2014) 25:747–59. doi: 10.1016/j.jvir.2014.01.025, PMID: 24630751CruiteISchroederMMerkleEMSirlinCB.
Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol. (2010) 195:29–41. doi: 10.2214/AJR.10.4538, PMID: 20566795GuoJSeoYRenSHongSLeeDKimS.
Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY). (2016) 41:1960–72. doi: 10.1007/s00261-016-0807-7, PMID: 27318936BharwaniNKohDM.
Diffusion-weighted imaging of the liver: an update. Cancer Imaging. (2013) 13:171–85. doi: 10.1102/1470-7330.2013.0019, PMID: 23598460HectorsSJLewisSKennedyPBaneOSaidDSegallM.
Assessment of hepatocellular carcinoma response to (90)Y radioembolization using dynamic contrast material-enhanced MRI and intravoxel incoherent motion diffusion-weighted imaging. Radiol Imaging Cancer. (2020) 2:e190094. doi: 10.1148/rycan.2020190094, PMID: 32803165TaouliBJohnsonRSHajduCHOeiMTMeradMYeeH.
Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol. (2013) 201:795–800. doi: 10.2214/AJR.12.9798, PMID: 24059368WeissJRuffCGrosseUGrözingerGHorgerMNikolaouK.
Assessment of hepatic perfusion using GRASP MRI: bringing liver MRI on a new level. Invest Radiol. (2019) 54:737–43. doi: 10.1097/RLI.0000000000000586, PMID: 31206392CheungALZhangLLiuCLiTCheungAHLeungC.
Evaluation of multisource adaptive MRI fusion for gross tumor volume delineation of hepatocellular carcinoma. Front Oncol. (2022) 12:816678. doi: 10.3389/fonc.2022.816678, PMID: 35280780ZhangLYinFFLuKMooreBHanSCaiJ.
Improving liver tumor image contrast and synthesizing novel tissue contrasts by adaptive multiparametric MRI fusion. Precis Radiat Oncol. (2022) 6:190–8. doi: 10.1002/pro6.1167, PMID: 36590077KokabiNCamachoJCXingMQiuDKitajimaHMittalPK.
Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging. (2014) 39:969–78. doi: 10.1007/s00261-014-0127-8, PMID: 24740759KimSMannelliLHajduCHBabbJSClarkTWHechtEM.
Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging. (2010) 31:348–55. doi: 10.1002/jmri.22038, PMID: 20099348MaleuxGHeyeSVaninbroukxJDerooseC.
Angiographic considerations in patients undergoing liver-directed radioembolization with 90Y microspheres. Acta Gastroenterol Belg. (2010) 73:489–96., PMID: 21299160HiattJRGabbayJBusuttilRW.
Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg. (1994) 220:50–2. doi: 10.1097/00000658-199407000-00008, PMID: 8024358MichelsNA.
Newer anatomy of the liver and its variant blood supply and collateral circulation. Am J Surg. (1966) 112:337–47. doi: 10.1016/0002-9610(66)90201-7, PMID: 5917302LiuDMSalemRBuiJTCourtneyABarakatOSergieZ.
Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. (2005) 16:911–35. doi: 10.1097/01.RVI.0000164324.79242.B2, PMID: 16002500LouieJDKotharyNKuoWTHwangGLHofmannLVGorisML.
Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol. (2009) 20:606–13. doi: 10.1016/j.jvir.2009.01.021, PMID: 19345589HeusnerTAHamamiMEErtleJHahnSPoeppelTHilgardP.
Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo. (2010) 182:603–8. doi: 10.1055/s-0029-1245192, PMID: 20183775RheeTKOmaryRAGatesVMounajjedTLarsonACBarakatO.
The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol. (2005) 16:1085–91. doi: 10.1097/01.RVI.0000177063.92678.21, PMID: 16105920GrözingerGKupferschlägerJDittmannHMaurerMGrosseUla FougèreC.
Assessment of the parenchymal blood volume by C-arm computed tomography for radioembolization dosimetry. Eur J Radiol. (2016) 85:1525–31. doi: 10.1016/j.ejrad.2016.06.005, PMID: 27501884Jafargholi RangrazECoudyzerWMaleuxGBaeteKDerooseCMNuytsJ.
Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. EJNMMI Res. (2019) 9:19. doi: 10.1186/s13550-019-0485-x, PMID: 30788640TanakaTAraiYInabaYInoueMNishiofukuHAnaiH.
Current role of hybrid CT/angiography system compared with C-arm cone beam CT for interventional oncology. Br J Radiol. (2014) 87:20140126. doi: 10.1259/bjr.20140126, PMID: 24968749LionbergANijhawanKNavuluriRZanganSVan HaTFunakiB.
Hybrid angiography-CT for transarterial radioembolization: a pictorial essay. Abdom Radiol (NY). (2021) 46:2850–4. doi: 10.1007/s00261-020-02914-8, PMID: 33394098CampbellGSReedDKDesaiASTL.
Liver tumor enhancement at hybrid angio-CT and comparison with tumor and hepatic parenchymal distribution of yttrium-90 microspheres by positron emission tomography. Cureus. (2023) 15:e49861. doi: 10.7759/cureus.49861, PMID: 38169929AhmadzadehfarHSabetABiermannKMuckleMBrockmannHKuhlC.
The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. (2010) 51:1206–12. doi: 10.2967/jnumed.109.074559, PMID: 20660379HamamiMEPoeppelTDMüllerSHeusnerTBockischAHilgardP.
SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. (2009) 50:688–92. doi: 10.2967/jnumed.108.058347, PMID: 19372479LenoirLEdelineJRollandYPrachtMRaoulJLArdissonV.
Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging. (2012) 39:872–80. doi: 10.1007/s00259-011-2033-4, PMID: 22237844GarinELenoirLRollandYEdelineJMesbahHLaffontS.
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. (2012) 53:255–63. doi: 10.2967/jnumed.111.094235, PMID: 22302962AtassiBBangashAKBahraniAPizziGLewandowskiRJRyuRK.
Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics. (2008) 28:81–99. doi: 10.1148/rg.281065721, PMID: 18203932UlielLRoyalHDDarcyMDZuckermanDASharmaASaadNE.
From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization–a comprehensive pictorial review. J Nucl Med. (2012) 53:1736–47. doi: 10.2967/jnumed.112.105361, PMID: 23124868Jafargholi RangrazETangXVan LaekenCMaleuxGDekervelJVan CutsemE.
Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition. EJNMMI Res. (2020) 10:94. doi: 10.1186/s13550-020-00675-5, PMID: 32797332WondergemMSmitsMLElschotMDe JongHWVerkooijenHMVan Den BoschMA.
99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. (2013) 54:1294–301. doi: 10.2967/jnumed.112.117614, PMID: 23749996DebebeSAAdjouadiMGulecSAFranquizJMcGoronAJ.
(90) Y SPECT/CT quantitative study and comparison of uptake with pretreatment (99 m) Tc-MAA SPECT/CT in radiomicrosphere therapy. J Appl Clin Med Phys. (2019) 20:30–42. doi: 10.1002/acm2.12512, PMID: 30628156ChengYWeiFYuHLingXGuoBShangJ.
(99m)Tc-MAA SPECT/CT imaging before (90)Y-SIRT for reflecting the distribution of (90)Y resin microspheres in tumors and the liver: a comparison with (90)Y PET/CT verification imaging. Quant Imaging Med Surg. (2025) 15:6272–86. doi: 10.21037/qims-24-2232, PMID: 40727337DemirBKucukNOSoydalCCelebiogluECInalGDursunE.
Comparative voxel-based dosimetry with pre-treatment Tc-99m SPECT/CT and post-treatment Y-90 PET/MRI for radioembolization with Y-90 microspheres. Ann Nucl Med. (2025) 39:716–31. doi: 10.1007/s12149-025-02052-5, PMID: 40266440TaswellCSStudenskiMPennixTStoverBGeorgiouMVenkatS.
For hepatocellular carcinoma treated with yttrium-90 microspheres, dose volumetrics on post-treatment bremsstrahlung SPECT/CT predict clinical outcomes. Cancers (Basel). (2023) 15. doi: 10.3390/cancers15030645, PMID: 36765603ElschotMVermolenBJLamMGDe KeizerBVan Den BoschMADe JongHW.
Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PloS One. (2013) 8:e55742. doi: 10.1371/journal.pone.0055742, PMID: 23405207FilippiLSchillaciOBagniO.
Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Rev Med Dev. (2019) 16:341–50. doi: 10.1080/17434440.2019.1608817, PMID: 30990129NaSJOhJKHyunSHLeeJWHongIKSongBI.
(18)F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: A multicenter retrospective cohort study. J Nucl Med. (2017) 58:730–6. doi: 10.2967/jnumed.116.182022, PMID: 27789714JreigeMMitsakisPVan Der GuchtAPomoniASilva-MonteiroMGnesinS.
(18)F-FDG PET/CT predicts survival after (90)Y transarterial radioembolization in unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. (2017) 44:1215–22. doi: 10.1007/s00259-017-3653-0, PMID: 28233086ReizineEChalayeJMuleSRegnaultHPerrinCCalderaroJ.
Utility of early posttreatment PET/CT evaluation using FDG or (18)F-FCH to predict response to (90)Y radioembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol. (2022) 218:359–69. doi: 10.2214/AJR.21.26485, PMID: 34494448KaoYHSteinbergJDTayYSLimGKYanJTownsendDW.
Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res. (2013) 3:57. doi: 10.1186/2191-219X-3-57, PMID: 23885971WillowsonKPTapnerMBaileyDL.
A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study. Eur J Nucl Med Mol Imaging. (2015) 42:1202–22. doi: 10.1007/s00259-015-3059-9, PMID: 25967868RoosenJKlaassenNJMWestlund GotbyLELOverduinCGVerheijMKonijnenbergMW.
To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging. (2021) 48:3776–90. doi: 10.1007/s00259-021-05340-0, PMID: 33839892LevillainHDuran DerijckereIMarinGGuiotTVoucheMReynaertN.
(90)Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI Res. (2018) 8:60. doi: 10.1186/s13550-018-0419-z, PMID: 30006851LinderPMLanWTrautweinNFBrosch-LenzJVon BeschwitzSKupferschlägerJ.
Optimization of Y-90 radioembolization imaging for post-treatment dosimetry on a long axial field-of-view PET/CT scanner. Diagn (Basel). (2023) 13. doi: 10.3390/diagnostics13223418, PMID: 37998554ZeimpekisKGSariHGözlügölNAchangwaNRShiKSchindewolfM.
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging. Eur J Nucl Med Mol Imaging. (2025) 52:1460–71. doi: 10.1007/s00259-024-07034-9, PMID: 39730786BashaMAAAlAzzazyMZAhmedAFYousefHYShehataSMEl SammakD.
Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study. Eur Radiol. (2018) 28:2592–603. doi: 10.1007/s00330-017-5232-y, PMID: 29368164JooIKimSYKangTWKimYKParkBJLeeYJ.
Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology. (2020) 296:335–45. doi: 10.1148/radiol.2020192275, PMID: 32484414Rodríguez-FraileMEzpondaAGrisantiFMoránVCalvoMBeriánP.
The joint use of (99m)Tc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning. EJNMMI Res. (2021) 11:23. doi: 10.1186/s13550-021-00764-z, PMID: 33661428KimEHOhJSChunHJChoiBGLeeHG.
Usefulness of fusion images of unenhanced and contrast-enhanced arterial phase cone-beam CT in the detection of viable hepatocellular carcinoma during transarterial chemoembolization. Diagn Interv Radiol. (2018) 24:262–7. doi: 10.5152/dir.2018.17503, PMID: 30211679KokabiNArndt-WebsterLChenBBrandonDSethiIDavarpanahfakhrA.
Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. (2023) 50:1743–52. doi: 10.1007/s00259-023-06111-9, PMID: 36650357FowlerKJMaughanNMLaforestRSaadNESharmaAOlsenJ.
PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol. (2016) 39:855–64. doi: 10.1007/s00270-015-1285-y, PMID: 26721589RheeTKNaikNKDengJAtassiBMulcahyMFKulikLM.
Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol. (2008) 19:1180–6. doi: 10.1016/j.jvir.2008.05.002, PMID: 18656011LevillainHBagniODerooseCMDieudonnéAGnesinSGrosserOS.
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. (2021) 48:1570–84. doi: 10.1007/s00259-020-05163-5, PMID: 33433699WuZOuyangSGaoJHuJGuoQLiuD.
Role of radiomics-based multiomics panel in the microenvironment and prognosis of hepatocellular carcinoma. Acad Radiol. (2025) 32:1961–70. doi: 10.1016/j.acra.2024.12.039, PMID: 39765431
Edited by: Denise Fabian, University of Kentucky, United States
Reviewed by: Han Lv, Capital Medical University, China